As a result of the IPO, the value of Arix’s stake in LogicBio has soared to almost £23mln, including the extra investment announced today
Newswires
Showing 25 of 5974
Three directors have subscribed for shares. Two independent directors have consulted with Futura's nomad and deemed that the terms of the participating directors' participation in the subscription are "fair and reasonable"
Chairman Peter Presland will take on a more active role to free up more time for CEO João Andrade to focus on sales and business development
ReNeuron thinks CTX could be reprogrammed and used to produce new non-donor-specific cell lines, including NK and T-Cells – the cells that can be modified to attack cancer cells
The approval from French regulators means Lojuxta will soon be available in all five of the EU’s largest markets
All of the current patients have received the escalated dose, meaning VAL201 is now on the home stretch of the early-stage study
“It’s really reassuring to ourselves within OptiBiotix and hopefully to investors that two big industry players…have committed large amounts of money to the company”
Orphan drug status gives drugmakers certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive
The results’ publication onto ClinicalTrials.gov gives them further validation
IXICO’s revenues rose 32% to £5.4mln in the 12 months ended September 30, boosted by the signing of several lucrative contracts
The US Patent Trial and Appeal Board found that Alnylam didn’t have enough evidence to prove a patent recently awarded to Silence should be invalidated
The biotech company said Dr Matt Johnson would present data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays
The biotechnology firm said it had been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis)
The firm said the proton beam had reached an energy of 52MeV, double the output energy needed to treat superficial tumours which it reached at the end of last month
Arix reckons the value of its stake will more than triple, but it isn’t cashing in just yet, instead it wants to buy up more shares at the IPO
The two are at loggerheads over the patented technology at the heart of the US group's first commercial drug
iQone was one of two acquisitions unveiled by Clinigen alongside last month’s full-year results
The biotech firm said under the agreement, US Pharma Lab Inc (USPL) would be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain
It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
On top of the Merck KGaA win, Physiomics inked deals with several other pharma and biotech groups last year
The healthcare property investor said one of the acquisitions was the Stratford Healthcare Centre, one of the largest primary healthcare facilities in the UK
The biotech and pharmaceuticals firm reported a pre-tax loss of £2.7mln for the period, almost £1mln less than the £3.6mln loss reported a year ago
Summit Therapeutics is on track to begin Phase III clinical trials of ridinilazole in the first quarter of next year
The biopharma firm said trials confirmed that iclaprim is non-inferior to vancomycin and significantly safer
2019 will be an important year for the firm with the re-start of Phase I/IIa trial for RXC004, part of a niche, and potentially breakthrough group of cancer drugs
